Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines
Open Access
- 16 February 2022
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-15
Abstract
V2p and V2i antibodies (Abs) that are specific for epitopes in the V1V2 region of the HIV gp120 envelope (Env) do not effectively neutralize HIV but mediate Fc-dependent anti-viral activities that have been correlated with protection from, or control of HIV, SIV and SHIV infections. Here, we describe a novel molecular toolbox that allows the discrimination of antigenically and functionally distinct polyclonal V2 Ab responses. We identify different patterns of V2 Ab induction by SHIV infection and three separate vaccine regimens that aid in fine-tuning an optimized immunization protocol for inducing V2p and V2i Abs. We observe no, or weak and sporadic V2p and V2i Abs in non-vaccinated SHIV-infected NHPs, but strong V2p and/or V2i Ab responses after immunization with a V2-targeting vaccine protocol. The V2-focused vaccination is superior to both natural infection and to immunization with whole Env constructs for inducing functional V2p- and V2i-specific responses. Strikingly, levels of V2-directed Abs correlate inversely with Abs specific for peptides of V3 and C5. These data demonstrate that a V1V2-targeting vaccine has advantages over the imprecise targeting of SIV/SHIV infections and of whole Env-based immunization regimens for inducing a more focused functional V2p- and V2i-specific Ab response.Keywords
All Related Versions
Funding Information
- U.S. Department of Health & Human Services | National Institutes of Health (R01 AI104387, R44 AI091546, P01 AI100151, R01 AI145655, P51 OD011092, P01 AI078064, U42 OD010426, P01 AI100151)
- South African Medical Research Council
- U.S. Department of Health & Human Services | National Institutes of Health
- U.S. Department of Health & Human Services | National Institutes of Health
- U.S. Department of Health & Human Services | National Institutes of Health
- U.S. Department of Health & Human Services | National Institutes of Health
- U.S. Department of Health & Human Services | National Institutes of Health
- U.S. Department of Health & Human Services | National Institutes of Health
- Icahn School of Medicine at Mount Sinai (Dept. Medicine)
- U.S. Department of Health & Human Services | National Institutes of Health
This publication has 96 references indexed in Scilit:
- Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy TrialPLOS ONE, 2013
- Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2Nature, 2012
- Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individualsVirology, 2012
- Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy TrialNew England Journal of Medicine, 2012
- Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeysNature, 2012
- Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9Nature, 2011
- Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in ThailandNew England Journal of Medicine, 2009
- Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine TargetScience, 2009
- Fc receptor-mediated antiviral antibodiesCurrent Opinion in HIV and AIDS, 2009
- Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1Molecular Immunology, 2009